


# UBS Strategy Xtra Balanced (USD)

## Performance Review

UBS (Lux) Strategy Xtra SICAV - Balanced (USD) (JPY hedged) P-acc



### Performance (basis JPY, net of fees)<sup>1</sup>



Past performance is not a reliable indicator of future results.

### Performance in % (net of fees)<sup>1</sup>

in %	2019	2020	2021	2022	2023 YTD <sup>2</sup>	Mar. 2023	5 years Ø p.a.	5 years
Fund (JPY)	9.93	6.28	6.85	-14.74	1.13	0.31	-0.72	-0.14

The performance shown does not take account of any commissions, entry or exit charges.

<sup>1</sup> These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management.  
<sup>2</sup> YTD: year-to-date (since beginning of the year)

**Markets continue to be impacted by persistent inflation figures and worries that monetary policy is going to stay restrictive for longer. Higher-than-anticipated interest rates resulted in some turmoil in the banking sector, sending out an additional signal of uncertainty and halting short-term financial market growth.**

### Monthly performance

In March the fund performed positively with 0.3%. In March risk assets recovered from the earlier pullback and continued their positive trend in the year to date. Returns across fixed income were also positive in March. Hedge funds saw negative returns, while risk parity was positive this month.

### YTD performance

YTD as of the end of March, the fund has delivered a positive performance of 1.1%. Both developed and emerging markets made a positive start to the year, with developed markets in particular performing strongly. Bond markets have performed positively this year. Hedge funds have seen negative returns, while risk parity has performed positively this year.

### Performance contributors

The highest contributors on the equity side were the Global Opportunity Sustainable and Global Sustainable strategies, followed by global, Japan, Hong Kong and Canada equities. Within fixed income, the USD High Grade and Corporate strategies, as well as the Inflation Linked Bonds strategy, were the biggest contributors.

### Performance detractors

The biggest detractors from performance on the equity side were US, UK and emerging market (EM) equities, as well as the Global Value strategy. There were no significant detractors on the fixed income side. However, hedge funds and risk parity detracted in March, as did currency hedging.

### For more information

UBS Fund Infoline: 0800 899 899

Internet: [www.ubs.com/funds](http://www.ubs.com/funds)

Contact your client advisor

### Portfolio management representatives

Sebastian Richner

Roland Kramer

Daniel Hammar

# UBS Strategy Xtra Balanced (USD)

## Current allocation by sub-asset class in %

	Current allocation
<b>Liquidity</b>	<b>5</b>
High grade bonds	10.0
USD inflation linked bonds	3.0
USD corporate bonds	10.0
EUR corporate bonds	0.0
USD high yield bonds	1.0
EUR high yield bonds	2.0
Emerging market sovereign bonds	5.0
Emerging market corporate bonds	2.0
Cash synth	0.3
Other fixed income	0.0
<b>Bonds</b>	<b>33.3</b>
Switzerland	1.0
United States	19.5
Eurozone	6.2
United Kingdom	1.3
Emerging markets	7.3
Japan	4.7
Canada	0.1
Australia	0.0
Sweden	3.0
Hong Kong	0.0
Singapore	0.2
Global	3.5
<b>Equities</b>	<b>46.7</b>
Hedge funds	11.0
Risk Parity	4.0
Commodity	0.0
<b>Alternative Investments</b>	<b>15</b>
<b>Total</b>	<b>100</b>

For illustrative purposes only. Current allocation may be changed at any time without prior notice. The allocation is based on the model portfolio of the strategy. Due to implementation exceptions, actual exposures may deviate. Foreign currency risks are largely hedged against the reference currency.

## 10 largest equity positions (%)

	Fund
Microsoft Corp	1.61
UnitedHealth Group Inc	0.74
Ameriprise Financial Inc	0.59
Adobe Inc	0.49
Taiwan Semiconductor Manufacturing Co Ltd	0.48
VMware Inc	0.47
Visa Inc	0.46
AXA SA	0.46
AstraZeneca PLC	0.42
London Stock Exchange Group PLC	0.42

## Current investment strategy

We increased our US corporate bond exposure by reducing our positions in US and global value equities. We are maintaining our positions in global value and EM equities, EM debt and US intermediate corporate bonds. In addition, we slightly reduced our position in USD long duration bonds. Furthermore, we are overweight in the AUD and underweight in the USD.

## Risks

The fund invests in equities, bonds of varying credit quality, money market securities on a global basis, as well as in alternative forms of investment such as hedge funds. It may therefore be subject to fluctuations in value. The fund may use derivatives which can reduce investment risk or give rise to additional risks (inter alia the counterparty risk). The fund can invest in less liquid assets that may be difficult to sell in the case of distressed markets. It therefore cannot be ruled out that the daily issue and redemption of fund units may be suspended temporarily. The value of a unit may fall below the purchase price. This requires an elevated risk tolerance and capacity. Every fund reveals specific risks, a description of these risks can be found in the prospectus.

## 5 largest bond issuers (%)

	Fund
United States Treasury Note/Bond	4.02
United States Treasury Inflation Indexed Bonds	2.07
United States Treasury Inflation Indexed Bonds - When Issued	0.72
International Bank for Reconstruction & Development	0.33
Amazon.com Inc	0.26

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

**For marketing and information purposes by UBS.** UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on [www.ubs.com/funds](http://www.ubs.com/funds). Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at [www.ubs.com/funds](http://www.ubs.com/funds). More explanations of financial terms can be found at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

© UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.